Twin brothers cash in on anaphylaxis device

The twin brothers who founded Richmond, VA-based Intelliject to develop a better injection device for adrenaline, which is used to treat severe allergic reactions (anaphylaxis), licensed the technology to Sanofi-Aventis for $25 million and $208 million in milestones.

Evan and Eric Edwards knew from personal experience that the devices they used to inject adrenaline were bulky and could be hard to use. They came up with a device the size of a credit card which is equipped with a voice chip that can be used to explain how to use it.

"We expect to make an FDA submission some time early next year," Neil Hughes, vice president of marketing, told Richmond Biz Sense. "Once we make the submission, it is up to them how long it takes to approve it, which is usually about a year."

- check out Intelliject release
- read the story from Richmond Biz Sense